Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth

Area of Science:

• Oncolytic virology
• Molecular and cellular biology
• Cancer research

Background:

• Seneca Valley Virus (SVV) is an oncolytic virus with potential for cancer therapy, particularly in neuroendocrine tumors.
• Tumor endothelial marker 8 (TEM8) is a cell surface receptor upregulated in various tumor types and associated stromal cells.
• The interaction between SVV and TEM8 was previously uncharacterized.

Purpose of the Study:

• To review the known interactions between SVV, TEM8, anthrax protective antigen (PA), and collagen VI.
• To explore the implications of the SVV-TEM8 interaction for cancer therapeutics.
• To discuss potential future therapeutic strategies targeting this pathway.

Main Methods:

• Literature review of studies on SVV, TEM8, anthrax toxin, and collagen VI.
• Analysis of the molecular mechanisms underlying the interaction between SVV and TEM8.
• Synthesis of current knowledge regarding these molecular players in cancer.

Main Results:

• SVV utilizes TEM8 as a cellular entry receptor, a mechanism shared with anthrax toxin's protective antigen (PA).
• TEM8's preferential upregulation in tumor cells and stromal compartments suggests a targeted entry mechanism for SVV.
• Collagen VI is identified as a native binding partner of TEM8, potentially influencing TEM8-mediated SVV entry.

Conclusions:

• The SVV-TEM8 interaction presents a novel target for oncolytic virotherapy.
• Understanding the interplay between SVV, TEM8, and its binding partners like collagen VI is crucial for developing effective cancer treatments.
• This review provides a foundation for future research into therapeutic applications leveraging the SVV-TEM8 axis.